[A19-12] Ipilimumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V

Last updated 15.08.2019

Project no.:
A19-12

Commission:
Commission awarded on 04.02.2019 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication/Intervention:

Treatment-naive adults with intermediate/poor-risk advanced renal cell carcinoma

Result of dossier assessment:

Indication of considerable added benefit for intermediate risk profile; indication of major added benefit for poor risk profile

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

15.05.2019

Nivolumab with ipilimumab: drug combination has added benefit in advanced renal cell carcinoma

Advantages in overall survival are not offset by serious disadvantages

Current document

Federal Joint Committee (G-BA)

2019-08-15 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.